CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “Therapeutic Modulation of RNA Using Oligonucleotides” Keystone Symposium held February 8-13, 2009 in Lake Louise, Alberta, Canada. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including respiratory syncytial virus (RSV), liver cancer, transthyretin (TTR) amyloidosis, and Ebola, as well as new data on delivery approaches for the delivery of RNAi therapeutics.
